联合心脑宁胶囊对脑梗死恢复期患者HMGB1/TLR4/NF-κB通路及脑中动脉血流的影响OACSTPCD
Effect of Xinnaoning Capsule on HMGB1/TLR4/NF-κB Pathway and Mid-dle Cerebral Artery Blood Flow in Patients with Convalescent Cerebral In-farction
目的 分析联合心脑宁胶囊对脑梗死恢复期患者高迁移率族蛋白B1(HMGB1)/Toll样受体4(TLR4)/核因子-κB(NF-κB)通路及脑中动脉血流的影响.方法 选取2019 年1 月至2023 年10 月收治的脑梗死恢复期患者82 例,采用抽签法分组,将采用依达拉奉治疗患者设为依达拉奉组,采用依达拉奉联合心脑宁胶囊治疗患者设为联合心脑宁组,每组41 例,均治疗2 周.统计2 组治疗2 周后的临床疗效及治疗期间不良反应发生情况,比较2 组治疗前…查看全部>>
Objective To analyze the effects of combined Xinnaoning capsule on high mobility group protein B1(HMGB1)/Toll-like receptor 4(TLR4)/nuclear factor-κB(NF-κB)pathway and middle cerebral artery blood flow in pa-tients with convalescent cerebral infarction.Methods A total of 82 patients with convalescent cerebral infarction admitted from January 2019 to October 2023 were selected.Using the lottery method,patients treated with Edaravone were assigned to Edaravone…查看全部>>
王健;席培林
012000 内蒙古自治区乌兰察布,乌兰察布市中心医院药剂科012000 内蒙古自治区乌兰察布,乌兰察布市中心医院神经内科
临床医学
脑梗死恢复期心脑宁胶囊依达拉奉高迁移率族蛋白B1Toll样受体4核因子-κB脑中动脉
Cerebral infarctionConvalescence periodXinnaoning capsuleEdaravoneHigh mobility group protein B1Toll-like receptor 4Nuclear factor-κBMiddle cerebral artery
《临床误诊误治》 2024 (14)
79-83,5
国家卫生健康委"十四五"规划重点课题(YYWS9439)
评论